Nurix Therapeutics Inc
NRIX11.260USD
+0.220+1.99%
Market hours （ET）Quotes delayed by 15 min
860.64MMarket Cap
LossP/E TTM
More Details of Nurix Therapeutics Inc Company
Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of targeted protein degradation medicines, which is aimed at improving treatment options for patients with cancer and inflammatory diseases. Its wholly owned, clinical-stage pipeline includes three investigational drug candidates: NX-5948, a highly selective degrader of Bruton’s tyrosine kinase (BTK); NX-2127, a dual degrader of BTK and transcription factors IKZF1(Ikaros) and IKZF3 (Aiolos); and NX-1607, an inhibitor of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. The Company is also advancing multiple degraders and degrader antibody conjugates (DACs) in its preclinical pipeline. Its partnered drug discovery pipeline consists of preclinical stage degraders of IRAK4 and STAT6, as well as multiple additional programs.
Company Info
Ticker SymbolNRIX
Company nameNurix Therapeutics Inc
IPO dateJul 24, 2020
CEODr. Arthur T. Sands, M.D., Ph.D.
Number of employees286
Security typeOrdinary Share
Fiscal year-endJul 24
Address1700 Owens St Ste 205
CitySAN FRANCISCO
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code94158
Phone14156605320
Websitehttps://www.nurixtx.com/
Ticker SymbolNRIX
IPO dateJul 24, 2020
CEODr. Arthur T. Sands, M.D., Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Arthur T. Sands, M.D., Ph.D.
Dr. Arthur T. Sands, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
908.33K
--
Dr. Christine Ring, J.D., Ph.D.
Dr. Christine Ring, J.D., Ph.D.
Chief Legal Officer, Chief Compliance Officer, Secretary
Chief Legal Officer, Chief Compliance Officer, Secretary
44.01K
+17.93%
Dr. David L. Lacey, M.D.
Dr. David L. Lacey, M.D.
Independent Director
Independent Director
33.33K
--
Mr. Hans van Houte
Mr. Hans van Houte
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Elizabeth Wolffe, Ph.D.
Ms. Elizabeth Wolffe, Ph.D.
Investor Relations
Investor Relations
--
--
Mr. Paul M. Silva
Mr. Paul M. Silva
Independent Director
Independent Director
--
--
Ms. Julia Paige Gregory
Ms. Julia Paige Gregory
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Edward C. (Ed) Saltzman
Mr. Edward C. (Ed) Saltzman
Independent Director
Independent Director
--
--
Dr. Roy D. Baynes, M.D., Ph.D.
Dr. Roy D. Baynes, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Lori A. Kunkel, M.D.
Dr. Lori A. Kunkel, M.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Arthur T. Sands, M.D., Ph.D.
Dr. Arthur T. Sands, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
908.33K
--
Dr. Christine Ring, J.D., Ph.D.
Dr. Christine Ring, J.D., Ph.D.
Chief Legal Officer, Chief Compliance Officer, Secretary
Chief Legal Officer, Chief Compliance Officer, Secretary
44.01K
+17.93%
Dr. David L. Lacey, M.D.
Dr. David L. Lacey, M.D.
Independent Director
Independent Director
33.33K
--
Mr. Hans van Houte
Mr. Hans van Houte
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Elizabeth Wolffe, Ph.D.
Ms. Elizabeth Wolffe, Ph.D.
Investor Relations
Investor Relations
--
--
Mr. Paul M. Silva
Mr. Paul M. Silva
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Fri, Aug 1
Updated: Fri, Aug 1
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
12.02%
BlackRock Institutional Trust Company, N.A.
7.81%
Deep Track Capital LP
7.19%
The Vanguard Group, Inc.
5.76%
Redmile Group, LLC
5.30%
Other
61.91%
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
12.02%
BlackRock Institutional Trust Company, N.A.
7.81%
Deep Track Capital LP
7.19%
The Vanguard Group, Inc.
5.76%
Redmile Group, LLC
5.30%
Other
61.91%
Shareholder Types
Shareholders
Proportion
Investment Advisor
44.05%
Hedge Fund
30.81%
Investment Advisor/Hedge Fund
29.53%
Research Firm
3.16%
Venture Capital
1.77%
Individual Investor
1.41%
Private Equity
0.97%
Pension Fund
0.47%
Sovereign Wealth Fund
0.42%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
377
87.00M
113.82%
-2.77M
2025Q1
389
86.54M
113.52%
-3.63M
2024Q4
375
82.62M
109.55%
+7.81M
2024Q3
364
70.42M
104.89%
-2.21M
2024Q2
348
68.70M
107.62%
+7.14M
2024Q1
317
52.13M
105.94%
-5.88M
2023Q4
312
49.16M
101.34%
-6.38M
2023Q3
304
48.27M
100.23%
-5.64M
2023Q2
307
47.72M
99.11%
-5.99M
2023Q1
304
45.84M
96.69%
-8.16M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Fidelity Management & Research Company LLC
9.19M
12.06%
-370.83K
-3.88%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
5.97M
7.83%
+323.12K
+5.72%
Mar 31, 2025
Deep Track Capital LP
5.50M
7.21%
+1.38M
+33.33%
Mar 31, 2025
The Vanguard Group, Inc.
4.40M
5.77%
+69.86K
+1.61%
Mar 31, 2025
Redmile Group, LLC
4.05M
5.32%
-140.70K
-3.36%
Mar 31, 2025
Commodore Capital LP
3.98M
5.22%
+128.91K
+3.35%
Mar 31, 2025
Baker Bros. Advisors LP
3.88M
5.09%
--
--
Mar 31, 2025
Wellington Management Company, LLP
3.19M
4.18%
-397.86K
-11.09%
Mar 31, 2025
State Street Global Advisors (US)
2.86M
3.75%
+57.96K
+2.07%
Mar 31, 2025
T. Rowe Price Associates, Inc.
2.82M
3.7%
-99.19K
-3.40%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
ARK Genomic Revolution ETF
1.72%
Tema Oncology ETF
1.25%
Virtus LifeSci Biotech Clinical Trials ETF
0.86%
SPDR S&P Biotech ETF
0.22%
iShares Micro-Cap ETF
0.19%
Direxion Daily S&P Biotech Bull 3X Shares
0.12%
Invesco Nasdaq Biotechnology ETF
0.1%
ProShares Ultra Nasdaq Biotechnology
0.1%
iShares Biotechnology ETF
0.09%
Fidelity Fundamental Small-Mid Cap ETF
0.08%
View more
ARK Genomic Revolution ETF
Proportion1.72%
Tema Oncology ETF
Proportion1.25%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.86%
SPDR S&P Biotech ETF
Proportion0.22%
iShares Micro-Cap ETF
Proportion0.19%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.12%
Invesco Nasdaq Biotechnology ETF
Proportion0.1%
ProShares Ultra Nasdaq Biotechnology
Proportion0.1%
iShares Biotechnology ETF
Proportion0.09%
Fidelity Fundamental Small-Mid Cap ETF
Proportion0.08%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
